On November 27, 2013, President Obama signed the Drug Quality and Security Act, which amends the Food, Drug and Cosmetic Act. The bill was passed by the U.S. Senate on November 18, without amendment, as several efforts to amend it were withdrawn or fell.
Originally introduced in the House of Representatives (as H.R. 3204), the bill significantly alters the regulation of compounded drugs. Among other things, the legislation will enhance regulation of such drugs by increasing government oversight with respect to those drugs that are especially prone to adverse events.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.